Consensus guidelines on the testing and clinical management issues associated with HLA and Non-HLA antibodies in transplantation

Transplantation

Volumn 95, Issue 1, 2013, Pages 19-47

  Tait, Brian D ^a   Süsal, Caner ^b   Gebel, Howard M ^c   Nickerson, Peter W ^d   Zachary, Andrea A ^e   Claas, Frans H J ^f   Reed, Elaine F ^g   Bray, Robert A ^c   Campbell, Patricia ^h   Chapman, Jeremy R ⁱ   Coates, P Toby ^j   Colvin, Robert B ^k   Cozzi, Emanuele ^l   Doxiadis, Ilias I N ^f   Fuggle, Susan V ^m   Gill, John ⁿ   Glotz, Denis ^o   Lachmann, Nils ^p   Mohanakumar, Thalachallour ^q   Suciu Foca, Nicole ^r   Sumitran Holgersson, Suchitra ^s   Tanabe, Kazunari ^t   Taylor, Craig J ^u   Tyan, Dolly B ^v   Webster, Angela ⁱ   Zeevi, Adriana ^w   Opelz, Gerhard ^b   more..

^a AUSTRALIAN RED CROSS BLOOD SERVICE   (Australia)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MANITOBA   (Canada)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF ALBERTA   (Canada)

ⁱ WESTMEAD HOSPITAL   (Australia)

^j Central and Northern Adelaide Renal and Transplantation Service   (Australia)

^k MASSACHUSETTS GENERAL HOSPITAL   (United States)

^l UNIVERSITY OF PADOVA   (Italy)

^m OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

ⁿ UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^o SAINT LOUIS HOSPITAL   (France)

^p CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^q WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^r NewYork Presbyterian Hospital   (United States)

^s UNIVERSITY OF GOTHENBURG   (Sweden)

^t TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^u ADDENBROOKE S HOSPITAL   (United Kingdom)

^v STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^w UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C4D; DONOR SPECIFIC ANTIBODY; ENDOTHELIAL CELL ANTIBODY; HLA ANTIBODY; HLA ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA CW ANTIGEN; HLA DPA ANTIGEN; HLA DPB ANTIGEN; HLA DQA ANTIGEN; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ARTICLE; BIOPSY TECHNIQUE; CELL ASSAY; COMPLEMENT DEPENDENT CYTOTOXICITY; COMPLEMENT FIXATION; CONSENSUS DEVELOPMENT; CORRELATION ANALYSIS; DENATURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE LOCUS; GRAFT FAILURE; GRAFT REJECTION; HEART TRANSPLANTATION; HIGH RISK PATIENT; HLA MATCHING; HUMAN; IMMUNOASSAY; INTESTINE TRANSPLANTATION; ITALY; KIDNEY TRANSPLANTATION; LABORATORY PERSONNEL; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; MEDICAL DECISION MAKING; MEDICAL EXPERT; MEDICAL SOCIETY; PANCREAS ISLET TRANSPLANTATION; PANCREAS TRANSPLANTATION; PATIENT MONITORING; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RISK ASSESSMENT; SOLID PHASE IMMUNOASSAY; TECHNOLOGY;

COMPLEMENT C1Q; COMPLEMENT C4B; COMPLEMENT SYSTEM PROTEINS; CYTOTOXICITY, IMMUNOLOGIC; FLOW CYTOMETRY; HLA ANTIGENS; HUMANS; IMMUNOASSAY; ISOANTIBODIES; ORGAN TRANSPLANTATION; PEPTIDE FRAGMENTS; PRACTICE GUIDELINES AS TOPIC;

EID: 84872057765     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31827a19cc     Document Type: Article

References (276)

1. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280: 735.
2. Feucht HE, Schneeberger H, Hillebrand G, et al. Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int 1993; 43: 1333.
3. Collins AB, Schneeberger EE, Pascual MA, et al. Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries. J Am Soc Nephrol 1999; 10: 2208.
4. Kerman RH, Susskind B, Buelow R, et al. Correlation of ELISAdetected IgG and IgA anti-HLA antibodies in pre-transplant sera with renal allograft rejection. Transplantation 1996; 62: 201.
5. Lee PC, Ozawa M. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation. In: Clinical Transplants. Los Angeles: The Terasaki Foundation Laboratory; 2007. pp. 219.
6. Terasaki PI, McClelland JD. Microdroplet assay of human serum cytotoxins. Nature 1964; 204: 998.
7. Garavoy MR, Rheinschmilt MA, Bigos M, et al. Flow cytometric analysis: a high technology crossmatch technique facilitating transplantation. Transplant Proc 1983; 15: 1939.
8. Zachary AA, Klingman L, Torne N, et al. Variations of the lymphocytotoxicity test. An evaluation of sensitivity and specificity. Transplantation 1995; 60: 498.
9. Chapman JR, Taylor CJ, Ting A, et al. Immunoglobulin class and specificity of antibodies causing positive T cell crossmatches: relationship with renal transplant outcome. Transplantation 1986; 42: 608.
10. Nelken D, Cohen I, Furcaig I. A method to increase the sensitivity of the lymphocyte microcytotoxicity test. Transplantation 1970; 10: 346.
11. Zachary AA, Ratner LE, Graziani JA, et al. Characterization of HLA class I specific antibodies by ELISA using solubilized antigen targets: II. Clinical relevance. Hum Immunol 2001; 62: 236.
12. Pei R, Lee J, Chen T, et al. Flow cytometric detection ofHLA antibodies using a spectrum of microbeads. Hum Immunol 1999; 60: 1293.
13. Pei R, Lee JH, Shih NJ, et al. Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. Transplantation 2003; 75: 43.
14. Mizutani K, Terasaki P, Hamdani E, et al. The importance of anti-HLA-specific antibody strength in monitoring kidney transplant patients. Am J Transplant 2007; 7: 1027.
15. Vaidya S. Clinical importance of anti-human leukocyte antigen-specific antibody concentration in performing calculated panel reactive antibody and virtual crossmatches. Transplantation 2008; 85: 1046.
16. Bray RA, Nolen JD, Larsen C, et al. Transplanting the highly sensitized patient: the Emory algorithm. Am J Transplant 2006; 6: 2307.
17. Kissmeyer-Nielsen F, Olsen S, Petersen VP, et al. Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells. Lancet 1966; 2: 662.
18. Claas FH, Witvliet MD, Duquesnoy RJ, et al. The acceptable mismatch program as a fast tool for highly sensitized patients awaiting a cadaveric kidney transplantation: short waiting time and excellent graft outcome. Transplantation 2004; 78: 190.
19. Doxiadis IIN, Witvliet M, Verduyn W, et al. The relevance of proficiency testing for laboratories involved in cadaveric organ transplantation and its consequences for graft survival. In: Clinical Transplants. Los Angeles: UCLA Immunogenetics Center; 2000. pp. 99.
20. Claas FHJ, DeMeester J, Witvliet MD, et al. Acceptable HLA mismatches for highly immunized patients. Rev Immunogenet 1999; 1: 351.
21. Duquesnoy RJ, Marrari M. Multilaboratory evaluation of serum analysis for HLA antibodies and crossmatch reactivity by lymphocytotoxicity methods. Arch Pathol Lab Med 2003; 127: 149.
22. Fuggle SV, Martin S. Tools for human leukocyte antigen antibody detection and their application to transplanting sensitized patients. Transplantation 2008; 86: 384.
23. Cecka JM, Kucheryavaya AY, Reinsmoen NL, et al. Calculated PRA: initial results show benefits for sensitized patients and a reduction in positive crossmatches. Am J Transplant 2011; 11: 719.
24. Couzi L, Araujo C, Guidicelli G, et al. Interpretation of positive flow cytometric crossmatch in the era of the single-antigen bead assay. Transplantation 2011; 91: 527.
25. Lobo PI, Spencer DE, Stevenson WC, et al. The use of Pronase digested human leukocytes to improve specificity of the flow cytometric crossmatch. Transpl Int 1995; 8: 472.
26. Hetrick SJ, Schillinger KP, Zachary AA, et al. Impact of Pronase on flow cytometric outcome. Hum Immunol 2011; 72: 330.
27. Taylor CJ, Kosmoliaptsis V, Summers DM, et al. Back to the future: application of contemporary technology to long-standing questions about the clinical relevance of HLA-specific alloantibodies in renal transplantation. Hum Immunol 2009; 70: 563.
28. Cai J, Terasaki PI. Post-transplantation antibody monitoring and HLA antibody epitope identification. Curr Opin Immunol 2008; 20: 602.
29. Kosmoliaptsis V, Bradley JA, Sharples LD, et al. Predicting the immunogenicity of human leukocyte antigen class I alloantigens using structural epitope analysis determined by HLAMatchmaker. Transplantation 2008; 85: 1817.
30. Duquesnoy RJ. HLAMatchmaker: a molecularly based algorithm for histocompatibility definition 1. Description of the algorithm. Hum Immunol 2002; 63: 339.
31. Dunn TB, Noreen H, Gillingham K, et al. Revisiting traditional risk factors for rejection and graft loss after kidney transplantation. Am J Transplant 2011; 11: 2132.
32. Billen EVA, Christiaans MHL, Doxiadis IIN, et al. HLA-DP antibodies before and after renal transplantation. Tissue Antigens 2010; 75: 278.
33. Niederhaus SV, Muth B, Lorentzen DF, et al. Luminex-based desensitization protocols: the University of Wisconsin initial experience. Transplantation 2011; 92: 12.
34. Higgins R, Lowe D, Hathaway M, et al. Human leukocyte antigen antibody-incompatible renal transplantation: excellent mediumterm outcomes with negative cytotoxic crossmatch. Transplantation 2011; 92: 900.
35. Cai J, Terasaki PI, Anderson N, et al. Intact HLA not A-2-m free heavy chain specific HLA class 1 antibodies are predictors of graft failure. Transplantation 2009; 88: 226.
36. Pereira S, Perkins S, Lee J-H, et al. Donor-specific antibody against denatured HLA-A1: clinically nonsignificant? Hum Immunol 2011; 72: 492.
37. Morales-Buenrostro LE, Terasaki PI, Marino-Vazquez LA, et al. "Natural" human leukocyte antigen antibodies found in nonalloimmunized health males. Transplantation 2008; 86: 1111.
38. El-Awar N, Terasaki PI, Nguyen A, et al. Epitopes of human leukocyte antigen class I antibodies found in sera of normal healthy males and cord blood. Hum Immunol 2009; 70: 844.
39. El-Awar N, Tersaki PI, Nguyen A, et al. Epitopes of HLA antibodies found in sera of normal healthy males and cord blood. In: Clinical Transplants. Los Angeles: The Terasaki Foundation Laboratory; 2008. pp. 199.
40. Poli F, Benazzi E, Innocente A, et al. Heart transplantation with donor-specific antibodies directed toward denatured HLA-A*02:01: a case report. Hum Immunol 2011; 72: 1045.
41. Zachary AA, Sholander JT, Houp JA, et al. Using real data for a virtual crossmatch. Hum Immunol 2009; 70: 574.
42. Tambur AR, Leventhal JR, Friedwald JJ, et al. The complexity of human leukocyte (HLA)-DQ antibodies and its effect on virtual crossmatching. Transplantation 2010; 90: 1117.
43. Locke JE, Zachary AA, Warren DS. Pro inflammatory events are associated with significant increases in breadth and strength of HLA specific antibody. Am J Transplant 2009; 9: 2136.
44. Amico P, Hirt-Minkowski P, Honger G, et al. Risk stratification by the virtual crossmatch: a prospective study in 233 renal transplantations. Transpl Int 2011; 24: 560.
45. Kosmoliaptsis V, Bradley JA, Peacock S, et al. Detection of immunoglobulin G human leukocyte antigen-specific alloantibodies in renal transplant patients using single-antigen-beads is compromised by the presence of immunoglobulin M human leukocyte antigenspecific alloantibodies. Transplantation 2009; 87: 813.
46. Schnaidt M, Weinstock C, Jurisic M, et al. HLA antibody specification using single-antigen beadsVa technical solution for the prozone effect. Transplantation 2011; 92: 510.
47. Weinstock C, Schnaidt M. The complement-mediated prozone effect in the Luminex single antigen bead assay and its impact on HLA antibody determination in patient sera. Int J Immunogenet 2012; [published online ahead of print August 23, 2012].
48. Mittag A, Tarnok A. Basis of standardization and calibration in cytometryVa review. J Biophotonics 2009; 2: 470.
49. Zachary A, Reinsmoen NL. Quantifying HLA-specific antibodies in patients undergoing desensitization. Curr Opin Organ Transplant 2011; 16: 410.
50. Waiser J, Budde K, Schütz M, et al. Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection. Nephrol Dial Transplant 2012; 27: 1246.
51. Waterboer T, Sehr P, Pawlita M. Suppression of non-specific binding in serological Luminex assays. J Immunol Methods 2006; 309: 200.
52. Earley MC, Vogt RF Jr, Shapiro HM, et al. Report from a workshop on multianalyte microsphere assays. Cytometry 2002; 50: 239.
53. Zachary AA, Lucas DP, Detrick B, et al. Naturally occurring interference in Luminex assays for HLA-specific antibodies: characteristics and resolution. Hum Immunol 2009; 70: 496.
54. Ravindranath MH, Kaneku H, El-Awar N, et al. Antibodies to HLA-E in nonalloimmunized males: pattern of HLA-Ia reactivity of anti-HLA-E-positive sera. J Immunol 2010; 185: 1935.
55. Ravindranath MH, Taniguchi M, Chen C-W, et al. HLA-E monoclonal antibodies recognize share peptide sequences on classical HLA class Ia: relevance to human natural HLA antibodies. Mol Immunol 2010; 47: 1121.
56. Newell H, Smith JD, Rogers P, et al. Sensitization following LVAD implantation using leucodepleted blood is not due to HLA antibodies. Am J Transplant 2006; 6: 1712.
57. Badders JL, Houp JA, Sholander JT, et al. Considerations in interpreting solid phase antibody data. Hum Immunol 2010; 71: S18.
58. Gloor JM, Moore SB, Schneider BA, et al. The effect of antithymocyte globulin on anti-human leukocyte antigen antibody detection assays. Transplantation 2007; 84: 258.
59. Masson E, Devillard N, Cabod J, et al. Misleading de novo detection of serum anti-HLA-A3 antibodies in kidney recipients having received ATG before transplantation. Transplantation 2010; 71: 170.
60. Wahrmann M, Exner M, Regele H, et al. Flow cytometry based detection of HLA alloantibody mediated classical complement activation. J Immunol Methods 2003; 275: 149.
61. Wahrmann M, Exner M, Haidbauer B, et al. [C4d]FlowPRA screeningVa specific assay for selective detection of complementactivating anti-HLA alloantibodies. Hum Immunol 2005; 66: 526.
62. Bartel G, Wahrmann M, Exner M, et al. In vitro detection of C4dfixing HLA alloantibodies: association with capillary C4d deposition in kidney allografts. Am J Trans 2008; 6: 41.
63. Smith JD, Hamour IM, Banner MR, et al. C4d fixing, Luminex binding antibodiesVa new tool for prediction of graft failure after heart transplantation. Am J Transplant 2007; 7: 2809.
64. Honger G, Wahrmann M, Patrizia A, et al. C4d-fixing capability of low-level donor-specific HLA antibodies is not predictive for early antibody-mediated rejection. Transplantation 2010; 89: 1471.
65. Smith JD, Banner NR, Hamour IM, et al. De novo donor HLAspecific antibodies after heart transplantation are an independent predictor of poor patient survival. Am J Transplant 2011; 11: 312.
66. Mizutani K, Gotoh M. C4d binding correlated with strong HLA antibodies involved in graft failures. Transplant Proc 2010; 42: 4021.
67. Chen G, Sequeira F, Tyan DB. Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads. Hum Immunol 2011; 72: 849.
68. Heeger PS. A complementary approach to treating antibody mediated transplant rejection. Kidney Int 2010; 78: 125.
69. Zeevi A, Marrari M, Feingold B, et al. Human leukocyte antigen epitope analysis to assess complement-and non-complementbinding donor-specific antibody repertoire in a pediatric heart transplant recipient. Hum Immunol 2012; 73: 48.
70. Chin C, Chen G, Sequeria F, et al. Clinical usefulness of a novel C1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients. J Heart Lung Transplant 2011; 30: 158.
71. Yabu JM, Higgins JP, Chen G, et al. C1q-fixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after kidney transplantation. Transplantation 2011; 91: 342.
72. Sutherland SM, Chen G, Sequeira FA, et al. Complement-fixing donor-specific antibodies identified by a novel C1q assay are associated with allograft loss. Pediatr Transplant 2012; 16: 12.
73. Otten HG, Verhaar MC, Borst HPE, et al. Pre-transplant donorspecific HLA class-I and-II antibodies are associated with an increased risk for kidney graft failure. Am J Transplant 2012; 12: 1618.
74. Zhang Q, Reed EF. Non-MHC antigenic targets of the humoral immune response in transplantation. Curr Opin Immunol 2010; 22: 682.
75. Bordron A, Revelen R, D'Arbonneau F, et al. Functional heterogeneity of anti-endothelial cell antibodies. Clin Exp Immunol 2001; 124: 492.
76. Glotz D, Lucchiari N, Pegaz-Fiornet B, et al. Endothelial cells as targets of allograft rejection. Transplantation 2006; 82: S19.
77. Sumitran-Karuppan S, Tyden G, Reinholt F, et al. Hyperacute rejections of two consecutive renal allografts and early loss of the third transplant caused by non-HLA antibodies specific for endothelial cells. Transpl Immunol 1997; 5: 321.
78. Le Bas-Bernardet S, Hourmant M, Coupel S, et al. Non-HLA-type endothelial cell reactive alloantibodies in pre-transplant sera of kidney recipients trigger apoptosis. Am J Transplant 2003; 3: 167.
79. Rodriguez PC, Arroyave IH, Mejia G, et al. Detection of alloantibodies against non-HLA antigens in kidney transplantation by flow cytometry. Clin Transplant 2000; 14: 472.
80. Ronda C, Borba SC, Ferreira SC, et al. Non-human leukocyte antigen antibodies reactive with endothelial cells could be involved in early loss of renal allografts. Transplant Proc 2011; 43: 1345.
81. Zhang Q, Cecka JM, Gjertson DW, et al. HLA and MICA: targets of antibody-mediated rejection in heart transplantation. Transplantation 2011; 91: 1153.
82. Pontes LF, Carvalho L, Stumbo AC, et al. Detection and localization of non-HLA-ABC antigenic sites relevant to kidney rejection on endothelial cells. J Immunol Methods 2001; 251: 73.
83. O'Donnell J, Mille-Baker B, Laffan M. Human umbilical vein endothelial cells differ from other endothelial cells in failing to express ABO blood group antigens. J Vasc Res 2000; 37: 540.
84. Hendrickx J, Doggen K, Weinberg EO, et al. Molecular diversity of cardiac endothelial cells in vitro and in vivo. Physiol Genomics 2004; 19: 198.
85. Moldobaeva A, Wagner EM. Difference in proangiogenic potential of systemic and pulmonary endothelium: role of CXCR2. Am J Physiol Lung Cell Mol Physiol 2005; 288: L1117.
86. Acevedo MJ, Caro-Oleas JL, Alvarez-Marquez AJ, et al. Antibodies against heterogeneous nuclear ribonucleoprotein K in patients with cardiac allograft vasculopathy. J Heart Lung Transplant 2011; 30: 1051.
87. Sun Q, Cheng Z, Cheng D, et al. De novo development of circulating anti-endothelial cell antibodies rather than pre-existing antibodies is associated with post-transplant allograft rejection. Kidney Int 2011; 79: 655.
88. Canet E, Devalliere J, Gerard N, et al. Profiling post-transplant circulating antibodies in kidney transplantation using donor endothelial cells. Transplantation 2012; 93: 257.
89. Valenzuela NM, Reed EF. The link between major histocompatibility complex antibodies and cell proliferation. Transplant Rev (Orlando) 2011; 25: 154.
90. Zhang X, Reed EF. Effect of antibodies on endothelium. Am J Transplant 2009; 9: 2459.
91. Jackson AM, Lucas DP, Melancon JK, et al. Clinical relevance and IgG subclass determination of non-HLA antibodies identified using endothelial cell precursors isolated from donor blood. Transplantation 2011; 92: 54.
92. Breimer ME, Rydberg L, Jackson AM, et al. Multicenter evaluation of a novel endothelial cell crossmatch test in kidney transplantation. Transplantation 2009; 87: 549.
93. Alheim M, Johansson SM, Hauzenberger D, et al. A flow cytometric crossmatch test for simultaneous detection of antibodies against donor lymphocytes and endothelial precursor cells. Tissue Antigens 2010; 75: 269.
94. Li L, Wadia P, Chen R, et al. Identifying compartment-specific non-HLA targets after renal transplantation by integrating transcriptome and "antibodyome" measures. Proc Natl Acad Sci USA 2009; 106: 4148.
95. Dinavahi R, George A, Tretin A, et al. Antibodies reactive to non-HLA antigens in transplant glomerulopathy. J Am Soc Nephrol 2011; 22: 1168.
96. Li L, Sigdel T, Vitalone M, et al. Differential immunogenicity and clinical relevance of kidney compartment specific antigens after renal transplantation. J Proteome Res 2010; 9: 6715.
97. Sigdel TK, Li L, Tran TQ, et al. Non-HLA antibodies to immunogenic epitopes predict the evolution of chronic renal allograft injury. J Am Soc Nephrol 2012; 23: 750.
98. Dib H, Tamby MC, Bussone G, et al. Targets of anti-endothelial cell antibodies in pulmonary hypertension and scleroderma. Eur Respir J 2012; 39: 1405.
99. Otten HG, van den Bosch JM, van Ginkel WG, et al. Identification of non-HLA target antigens recognized after lung transplantation. J Heart Lung Transplant 2006; 25: 1425.
100. Hankey KG, Drachenberg CB, Papadimitriou JC, et al. MIC expression in renal and pancreatic allografts. Transplantation 2002; 73: 304.
101. Quiroga I, Salio M, Koo DD, et al. Expression of MHC class I-related chain B (MICB) molecules on renal transplant biopsies. Transplantation 2006; 81: 1196.
102. Sahin U, Tureci O, Pfreundschuh M. Serological identification of human tumor antigens. Curr Opin Immunol 1997; 9: 709.
103. Azimzadeh AM, Pfeiffer S, Wu GS, et al. Humoral immunity to vimentin is associated with cardiac allograft injury in nonhuman primates. Am J Transplant 2005; 5: 2349.
104. Barber LD, Whitelegg A, Madrigal JA, et al. Detection of vimentinspecific autoreactive CD8+ T cells in cardiac transplant patients. Transplantation 2004; 77: 1604.
105. Jurcevic S, Ainsworth ME, Pomerance A, et al. Antivimentin antibodies are an independent predictor of transplant-associated coronary artery disease after cardiac transplantation. Transplantation 2001; 71: 886.
106. Leong HS, Mahesh BM, Day JR, et al. Vimentin autoantibodies induce platelet activation and formation of platelet-leukocyte conjugates via platelet-activating factor. J Leukoc Biol 2008; 83: 263.
107. Dragun D, Muller DN, Brasen JH, et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005; 352: 558.
108. Reinsmoen NL, Lai CH, Heidecke H, et al. Anti-angiotensin type 1 receptor antibodies associated with antibody mediated rejection in donor HLA antibody negative patients. Transplantation 2010; 90: 1473.
109. Goers TA, Ramachandran S, Aloush A, et al. De novo production of K-alpha1 tubulin-specific antibodies: role in chronic lung allograft rejection. J Immunol 2008; 180: 4487.
110. Nath DS, Tiriveedhi V, Basha HI, et al. A role for antibodies to human leukocyte antigens, collagen-V, and K-alpha1-tubulin in antibodymediated rejection and cardiac allograft vasculopathy. Transplantation 2011; 91: 1036.
111. Morgun A, Shulzhenko N, Unterkircher CS, et al. Pre-and posttransplant anti-myosin and anti-heat shock protein antibodies and cardiac transplant outcome. J Heart Lung Transplant 2004; 23: 204.
112. Warraich RS, Pomerance A, Stanley A, et al. Cardiac myosin autoantibodies and acute rejection after heart transplantation in patients with dilated cardiomyopathy. Transplantation 2000; 69: 1609.
113. Burlingham WJ, Love RB, Jankowska-Gan E, et al. IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants. J Clin Invest 2007; 117: 3498.
114. Saini D, Weber J, Ramachandran S, et al. Alloimmunity-induced autoimmunity as a potential mechanism in the pathogenesis of chronic rejection of human lung allografts. J Heart Lung Transplant 2011; 30: 624.
115. Reed EF, Rao P, Zhang Z, et al. Comprehensive assessment and standardization of solid phase platforms for the detection of antibodies to HLA. Am J Transplant. 2012; In press.
116. Gebel HM, Bray RA, Nickerson P. Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: contraindication vs. risk. Am J Transplant 2003; 3: 1488.
117. Bryan CF, McDonald SB, Luger LM, et al. Successful renal transplantation despite low levels of donor-specific HLA class I antibody without IVIg or plasmapheresis. Clin Transplant 2006: 20: 563.
118. Gibney EM, Cagle LR, Freed B, et al. Detection of donor-specific antibodies using HLA-coated microspheres: another tool for kidney transplant risk stratification. Nephrol Dial Transplant 2006; 21: 2625.
119. Patel AM, Pancoska C, Mulgoankar S, et al. Renal transplantation in patients with pre-transplant donor-specific antibodies and negative flow cytometry crossmatches. Am J Transplant 2007; 7: 2371.
120. Burns JM, Cornell LD, Perry DK, et al. Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation. Am J Transplant 2008; 8: 2684.
121. Eng HS, Bennett JG, Tsiopelas E, et al. Anti-HLA donor-specific antibodies detected in positive B-cell crossmatches by Luminex predict late graft loss. Am J Transplant 2008; 8: 2335.
122. Van Den Berg-Loonen E, Billen EVA, Voorter CEM, et al. Clinical relevance of pre-transplant donor-directed antibodies detected by single antigen beads in highly sensitized renal transplant patients. Transplantation 2008; 85: 1086.
123. Aubert V, Venetz J-P, Pantaleo G, et al. Low levels of human leukocyte antigen donor-specific antibodies detected by solid phase assay before transplantation are frequently clinically irrelevant. Hum Immunol 2009; 70: 580.
124. Vlad G, Ho E-K, Valsilescu ER, et al. Relevance of different antibody detection methods for the prediction of antibody-mediated rejection and deceased-donor kidney allograft survival. Hum Immunol 2009; 70: 589.
125. Phelan D, Mohanakumar T, Ramachandran S, et al. Living donor renal transplantation in the presence of donor-specific human leukocyte antigen antibody detected by solid-phase assay. Hum Immunol 2009; 70: 584.
126. Gupta A, Sinnott P. Clinical relevance of pre-transplant human leukocyte antigen donor-specific antibodies in renal patients waiting for a transplant: a risk factor. Hum Immunol 2009; 70: 618.
127. Amico P, Honger G, Mayr M, et al. Clinical relevance of pre-transplant donor-specific HLA antibodies detected by single-antigen flow-beads. Transplantation 2009; 87: 1681.
128. Riethmuller S, Ferrari-Lacraz S, Muller MK, et al. Donor-specific antibody levels and three generations of crossmatches to predict antibody-mediated rejection in kidney transplantation. Transplantation 2010; 90: 160.
129. Singh N, Djamali A, Lorentzen D, et al. Pre-transplant donor-specific antibodies detected by single-antigen bead flow cytometry are associated with inferior kidney transplant outcomes. Transplantation 2010; 90: 1079.
130. Gloor JM, Winters JL, Cornell LD, et al. Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation. Am J Transplant 2010; 10: 582.
131. Lefaucher C, Loupy A, Hill GS, et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010; 21: 1398.
132. Ishida H, Hirai T, Kohei N, et al. Significance of qualitative and quantitative evaluations of anti-HLA antibodies in kidney transplantation. Transpl Int 2011; 24: 150.
133. Süsal C, Ovens J, Mahmoud K, et al. No association of kidney graft loss with human leukocyte antigen antibodies detected exclusively by sensitive Luminex single-antigen testing: a Collaborative Transplant Study report. Transplantation 2011; 91: 881.
134. Caro-Oleas JL, Gonzalez-Escribano MF, Gonzalez-Roncero FM, et al. Clinical relevance of HLA donor-specific antibodies detected by single antigen assay in kidney transplantation. Nephrol Dial Transplant 2012; 27: 1231.
135. Loupy A, Hill GS, SuberBielle C, et al. Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with pre-formed donor-specific antibodies (DSA). Am J Transplant 2011; 11: 56.
136. Montgomery RA, Lonze BE, King KE, et al. Desensitization in HLAincompatible kidney recipients and survival. NEngl JMed 2011; 365: 318.
137. Bartel G, Wahrmann M, Regele H, et al. Peritransplant immunoadsorption for positive crossmatch deceased donor kidney transplantation. Am J Transplant 2010; 10: 2033.
138. Morath C, Beimler J, Opelz G, et al. Living donor kidney transplantation in crossmatch-positive patients enabled by peritransplant immunoadsorption and anti-CD20 therapy. Transpl Int 2012; 25: 506.
139. Morath C, Beimler J, Opelz G, et al. An integrative approach for the transplantation of high-risk sensitized patients. Transplantation 2010; 90: 645.
140. Bishay ES, Cook DJ, Starling RC, et al. The clinical significance of flow cytometry crossmatching in heart transplantation. Eur J Cardiothorac Surg 2000; 17: 362.
141. Bishay ES, Cook DJ, El Fettouh H, et al. The impact of HLA sensitization and donor cause of death in heart transplantation. Transplantation 2000; 70: 220.
142. Michaels PJ, Espejo ML, Kobashigawa J, et al. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant 2003; 22: 58.
143. Jacobs JP, Quintessenza JA, Boucek RJ, et al. Pediatric cardiac transplantation in children with high panel reactive antibody. Ann Thorac Surg 2004; 78: 1703.
144. Di Filippo S, Girnita A, Webber SA, et al. Impact of ELISA-detected anti-HLA antibodies on pediatric cardiac allograft outcome. Hum Immunol 2005; 66: 513.
145. Leech SH, Lopez-Cepero M, LeFor WM, et al. Management of the sensitized cardiac recipient: the use of plasmapheresis and intravenous immunoglobulin. Clin Transplant 2006; 20: 476.
146. Feingold B, Bowman P, Zeevi A, et al. Survival in allosensitized children after listing for cardiac transplantation. J Heart Lung Transplant 2007; 26: 565.
147. Opelz G, Dohler B, Susal C. Analysis of positive kidney, heart, and liver transplant crossmatches reported to the Collaborative Transplant Study. Hum Immunol 2009; 70: 627.
148. Rose ML, Smith JD. Clinical relevance of complement-fixing antibodies in cardiac transplantation. Hum Immunol 2009; 70: 605.
149. Ho EK, Vlad G, Colovai AI, et al. Alloantibodies in heart transplantation. Hum Immunol 2009; 70: 825.
150. Scott V, Williams RJ, Levi DS. Outcomes of cardiac transplantation in highly sensitized pediatric patients. Pediatr Cardiol 2011; 32: 615.
151. Mahle WT, Tresler MA, Edens RE, et al. Pediatric Heart Transplant Study Group. Allosensitization and outcomes in pediatric heart transplantation. J Heart Lung Transplant 2011; 30: 1221.
152. Kobashigawa JA, Patel JK, Kittleson MM, et al. The long-term outcome of treated sensitized patients who undergo heart transplantation. Clin Transplant 2011; 25: E61.
153. Gandhi MJ, DeGoey SR, Bundy K, et al. Effect of pre-transplant human leukocyte antigen antibodies detected by solid-phase assay on heart transplant outcomes. Transplant Proc 2011; 43: 3840.
154. Lau CL, Palmer SM, Posther KE, et al. Influence of panel-reactive antibodies on post-transplant outcomes in lung transplant recipients. Ann Thorac Surg 2000; 69: 1520.
155. Appel JZ 3rd, Hartwig MG, Davis RD, et al. Utility of peritransplant and rescue intravenous immunoglobulin and extracorporeal immunoadsorption in lung transplant recipients sensitized to HLA antigens. Hum Immunol 2005; 66: 378.
156. Hadjiliadis D, Chaparro C, Reinsmoen NL, et al. Pre-transplant panel reactive antibody in lung transplant recipients is associated with significantly worse post-transplant survival in a multicenter study. J Heart Lung Transplant 2005; 24: 249.
157. Appel JZ 3rd, Hartwig MG, Cantu E 3rd, et al. Role of flow cytometry to define unacceptable HLA antigens in lung transplant recipients with HLA-specific antibodies. Transplantation 2006; 81: 1049.
158. Shah AS, Nwakanma L, Simpkins C, et al. Pre-transplant panel reactive antibodies in human lung transplantation: an analysis of over 10, 000 patients. Ann Thorac Surg 2008; 85: 1919.
159. Stuckey LJ, Kamoun M, Chan KM. Lung transplantation across donor-specific anti-human leukocyte antigen antibodies: utility of bortezomib therapy in early graft dysfunction. Ann Pharmacother 2011; 46: e2.
160. Mangi AA, Mason DP, Nowicki ER, et al. Predictors of acute rejection after lung transplantation. Ann Thorac Surg 2011; 91: 1754.
161. Fung J, Makowka L, Tzakis A, et al. Combined liver-kidney transplantation: analysis of patients with preformed lymphocytotoxic antibodies. Transplant Proc 1988; 20: 88.
162. Muro M, Marin L, Miras M, et al. Liver recipients harboring antidonor
163. Mosconi G, Scolari MP, Feliciangeli G, et al. Combined liver-kidney transplantation with preformed anti-HLA antibodies: a case report. Transplant Proc 2006; 38: 1125.
164. Castillo-Rama M, Castro MJ, Bernardo I, et al. Preformed antibodies detected by cytotoxic assay or multibead array decrease liver allograft survival: role of human leukocyte antigen compatibility. Liver Transpl 2008; 14: 554.
165. Reichman TW, Marino SR, Milner J, et al. Acute humoral rejection in an ABO compatible combined liver-kidney transplantVthe kidney is not always protected. Am J Transplant 2009; 9: 1957.
166. Goh A, Scalamogna M, De Feo T, et al. Human leukocyte antigen crossmatch testing is important for liver re-transplantation. Liver Transpl 2010; 16: 308.
167. Girnita A, Mazariegos GV, Castellaneta A, et al. A. Liver transplant recipients weaned off immunosuppression lack circulating donorspecific antibodies. Hum Immunol 2010; 71: 274.
168. Musat A, Agni RM, Wai PY, et al. The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation. Am J Transplant 2011; 11: 500.
169. Dar W, Agarwal A, Watkins C, et al. Donor-derived MHC class I antibody is preferentially cleared from sensitized recipients of combined liver/kidney transplants. Am J Transplant 2011; 11: 841.
170. O'Leary JG, Kaneku H, Susskind BM, et al. High mean fluorescence intensity donor-specific anti-HLA antibodies associated with chronic rejection post liver transplant. Am J Transplant 2011; 11: 1868.
171. Askar M, Schold JD, Eghtesad B, et al. Combined liver-kidney transplants: allosensitization and recipient outcomes. Transplantation 2011; 91: 1286.
172. Lunz J, Ruppert KM, Cajaiba MM, et al. Re-examination of the lymphocytotoxic crossmatch in liver transplantation: can C4d stains help in monitoring? Am J Transplant 2012; 12: 171.
173. Melcher ML, Olson JL, Baxter-Lowe LA, et al. Antibody-mediated rejection of a pancreas allograft. Am J Transplant 2006; 6: 423.
174. Kato T, Mizutani P, Terasaki P, et al. Association of emergence of HLA and acute rejection in intestinal transplant recipients: a possible evidence of acute humoral sensitization. Transplant Proc 2006; 38: 1735.
175. Sindhi R, Ashokkumar C, Mazariegos G, et al. Immune monitoring in small bowel transplantation. Curr Opin Organ Transplant 2010; 15: 349.
176. Ruiz P, Carreno M, Weppler D, et al. Immediate antibody-mediated (hyperacute) rejection in small-bowel transplantation and relationship to crossmatch status and donor-specific C4d binding antibodies: case report. Transplant Proc 2010; 42: 95.
177. Wu G, Lunz J, Costa G, et al. Donor specific human leukocyte antigen antibodies and visceral transplantation: outcome analysis with special reference to the liver-contained allografts. Transplantation 2010; 90: 358.
178. Ashokkumar C, Zeevi A, Bentlejewski C, et al. Circulating donorspecific anti-HLA antibody may identify rejection-prone pediatric small bowel transplant. Transplantation 2010; 90: 403.
179. Tsai L, Island E, Chang JW, et al. Association between donor-specific antibodies and acute rejection and resolution in small bowel and multivisceral transplantation. Transplantation 2011; 92: 709.
180. Mohanakumar T, Narayanan K, Desai N, et al. A significant role for histocompatibility in human islet transplantation. Transplantation 2006; 82: 180.
181. Campbell PM, Salam A, Ryan EA, et al. Pre-transplant HLA antibodies are associated with reduced graft failure after clinical islet transplantation. Am J Transplant 2007; 7: 1242.
182. Cardani R, Pileggi A, Ricordi C, et al. Allosensitization of islet allograft recipients. Transplantation 2007; 84: 1413.
183. Naziruddin B, Wease S, Stablein D, et al. HLA Class I sensitization in islet transplant recipients-reports from the Collaborative Islet Transplant Registry. Cell Transplantation 2012; 21: 901.
184. Drachenberg CB, Torrealba JR, Nankivell BJ, et al. Guidelines for the diagnosis of antibody-mediated rejection in pancreas allograftsupdated Banff grading schema. Am J Transplant 2011; 11: 1792.
185. Shin YS, Yang CW, Ahn HJ, et al. Clinical significance of antiendothelial cell antibody in renal transplant recipients. Kor J Intern Med 2001; 16: 24.
186. Sumitran-Holgersson S, Wilczek HE, Holgersson J, et al. Identification of the nonclassical HLA molecules, MICA, as targets for humoral immunity associated with irreversible rejection of kidney allografts. Transplantation 2002; 27: 268.
187. Opelz G; Collaborative Transplant Study. Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies. Lancet 2005; 365: 1570.
188. Zou Y, Stastny P, Süsal C, et al. Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med 2007; 357: 1293.
189. Grandtnerová B, Laca L, Jahnová E, et al. Hyperacute rejection of living related kidney graft caused by IgG endothelial specific antibodies with a negative monocyte cross-match. Ann Transplant 2002; 7: 52.
190. Han F, Lv R, Jin J, et al. Pre-transplant serum concentrations of antiendothelial cell antibody in panel reactive antibody negative renal recipients and its impact on acute rejection. Clin Chem Lab Med 2009; 47: 1265.
191. Ismail AM, Badawi RM, El-Agroudy AE, et al. Pre-transplant detection of anti-endothelial cell antibodies could predict renal allograft outcome. Exp Clin Transplant 2009; 7: 104.
192. Montgomery RA, Locke JE, King KE, et al. ABO incompatible renal transplantation: a paradigm ready for broad implementation. Transplantation 2009; 87: 1246.
193. Toki D, Ishida H, Setoguchi K, et al. Acute antibody-mediated rejection in living ABO-incompatible kidney transplantation: longterm impact and risk factors. Am J Transplant 2009; 9: 567.
194. Narayan S, Tsai EW, Zhang Q, et al. Acute rejection associated with donor-specific anti-MICA antibody in a highly sensitized pediatric renal transplant recipient. Pediatr Transplant 2011; 15: E1.
195. Kerman R. Clinical histocompatibility workshop. PuntaCana, Dominican Republic. Canoga Park, Ca: One Lambda Inc. ; 2011.
196. Flint SM, Walker RG, Hogan C, et al. Successful ABO-incompatible kidney transplantation with antibody removal and standard immunosuppression. Am J Transplant 2011; 11: 1016.
197. Chung BH, Lee JY, Kang SH, et al. Comparison of patient outcome according to renal replacement modality after renal allograft failure. Ren Fail 2011; 33: 150.
198. Cox ST, Stephens HA, Fernando R, et al. Major histocompatibility complex class I-related chain A allele mismatching, antibodies, and rejection in renal transplantation. Hum Immunol 2011; 72: 827.
199. Solgi G, Furst D, Mytilineos J, et al. Clinical relevance of pre and post-transplant immune markers in kidney allograft recipients: anti-HLA and MICA antibodies and serum levels of sCD30 and sMICA. Transpl Immunol 2012; 26: 81.
200. Latif N, Rose ML, Yacoub MH, et al. Association of pre-transplantation anti-heart antibodies with clinical course after heart transplantation. J Heart Lung Transplant 1995; 14: 119.
201. Suárez-Alvarez B, Ló pez-Vázquez A, D́az-Peña R, et al. Posttransplant soluble MICA and MICA antibodies predict subsequent heart graft outcome. Transpl Immunol 2006; 17: 43.
202. Suárez-Alvarez B, Ló pez-Vázquez A, Gonzalez MZ, et al. The relationship of anti-MICA antibodies and MICA expression with heart allograft rejection. Am J Transplant 2007; 7: 1842.
203. Roche SL, Burch M, O'Sullivan J, et al. Multicenter experience of ABO-incompatible pediatric cardiac transplantation. Am J Transplant 2008; 8: 208.
204. Smith JD, Hamour IM, Burke MM, et al. A reevaluation of the role of IgM Non-HLA antibodies in cardiac transplantation. Transplantation 2009; 87: 864.
205. Smith JD, Brunner VM, Jigjidsuren S, et al. Lack of effect of MICA antibodies on graft survival following heart transplantation. Am J Transplant 2009; 9: 1912.
206. Dipchand AI, Pollock BarZiv SM, Manlhiot C, et al. Equivalent outcomes for pediatric heart transplantation recipients: ABO-blood group incompatible versus ABO-compatible. Am J Transplant 2010; 10: 389.
207. Smith JD, Crisp SJ, Dunn MJ, et al. Pre-transplant anti-epithelial cell antibodies and graft failure after single lung transplantation. Transpl Immunol 1995; 3: 68.
208. Iwata T, Philipovskiy A, Fisher AJ, et al. Anti-type V collagen humoral immunity in lung transplant primary graft dysfunction. J Immunol 2008; 181: 5738.
209. Bharat A, Saini D, Steward N, et al. Antibodies to self-antigens predispose to primary lung allograft dysfunction and chronic rejection. Ann Thorac Surg 2010; 90: 1094.
210. Jaeger C, Hering BJ, Hatziagelaki E, et al. Glutamic acid decarboxylase antibodies are more frequent than islet cell antibodies in islet transplanted IDDM patients and persist or occur despite immunosuppression. J Mol Med (Berl) 1999; 77: 45.
211. Huurman VA, Hilbrands R, Pinkse GG, et al. Cellular islet autoimmunity associates with clinical outcome of islet cell transplantation. PLoS One 2008; 3: e2435.
212. Bosi E, Braghi S, Maffi P, et al. Autoantibody response to islet transplantation in type 1 diabetes. Diabetes 2001; 50: 2464.
213. Lemy A, Andrien M, Wissing KM, et al. Major histocompatibility complex class 1 chain-related antigen A antibodies: sensitizing events and impact on renal graft outcomes. Transplantation 2010; 90: 168.
214. Racusen LC, Colvin RB, Solez K, et al. Antibody-mediated rejection criterion addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708.
215. Solez K, Colvin RB, Racusen LC, et al. Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007; 7: 518.
216. Mengel M, Sis B, Haas M, et al. Banff 2011Meeting report: new concepts in antibody-mediated rejection. Am J Transplant 2012; 12: 563.
217. Einecke G, Sis B, Reeve J, et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009; 9: 2520.
218. Sis B, Jhangri GS, Bunnag S, et al. Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am J Transplant 2009; 9: 2312.
219. Kobashigawa J, Crespo-Leiro MG, Ensminger SM, et al. Report from a consensus conference on antibody-mediated rejection in heart transplantation. J Heart Lung Transplant 2011; 30: 252.
220. Girnita A. L, McCurry KR, Iacono AT, et al. HLA-specific antibodies are associated with high-grade and persistent-recurrent lung allograft acute rejection. J Heart Lung Transplant 2004; 23: 1135.
221. Hachem RR, Yusen RD, Meyers BF, et al. Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy after lung transplantation. J Heart Lung Transplant 2010; 29: 973.
222. Martinu T, Chen DF, Palmer SM. Acute rejection and humoral sensitization in lung transplant recipients. Proc Am Thorac Soc 2009; 6: 54.
223. Sundaresan S, Mohanakumar T, Smith MA, et al. HLA-A locus mismatches and development of antibodies to HLA after lung transplantation correlate with the development of bronchiolitis obliterans syndrome. Transplantation 1998; 65: 648.
224. Palmer SM, Davis RD, Hadjiliadis D, et al. Development of an antibody specific to major histocompatibility antigens detectable by flow cytometry after lung transplant is associated with bronchiolitis obliterans syndrome. Transplantation 2002; 74: 799.
225. Trulock EP, Christie JD, Edwards LB, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult lung and heart-lung transplantation report-2007. J Heart Lung Transplant 2007; 26: 782.
226. Piemonti L, Everly MJ, Maffi P, et al. Both alloantibodies and autoantibodies are a significant barrier to preservation of islet cell function after transplantation. Transpl Int 2011; 24: 47.
227. Kfoury AG, Stehlik J, Renlund DG, et al. Impact of repetitive episodes of antibody-mediated or cellular rejection on cardiovascular mortality in cardiac transplant recipients: defining rejection patterns. J Heart Lung Transplant 2006; 25: 1277.
228. Tambur AR, Pamboukian SV, Costanzo MR, et al. The presence of HLA-directed antibodies after heart transplantation is associated with poor allograft outcome. Transplantation 2005; 80: 1019.
229. Taylor DO, Yowell RL, Kfoury AG, et al. Allograft coronary artery disease: clinical correlations with circulating anti-HLA antibodies and the immunohistopathologic pattern of vascular rejection. J Heart Lung Transplant 2000; 19: 518.
230. Lefaucheur C, Nochy D, Hill GS, et al. Determinants of poor graft outcome in patients with antibody-mediated acute rejection. Am J Transplant 2007; 7: 832.
231. Kraus ES, Parekh RS, Oberai P, et al. Subclinical rejection in stable positive crossmatch kidney transplant patients: incidence and correlations. Am J Transplant 2009; 9: 1826.
232. Bachler K, Amico P, Honger G, et al. Efficacy of induction therapy with ATG and intravenous immunoglobulin in patients with lowlevel donor-specific HLA antibodies. Am J Transplant 2010; 10: 1254.
233. El-Zoghby ZM, Stegall MD, Lager DJ, et al. Identifying specific causes of kidney allograft loss. Am J Transplant 2009; 9: 527.
234. Matas AJ, Leduc R, Rush D, et al. Histopathologic clusters differentiate subgroups within the nonspecific diagnoses of CAN or CR: preliminary data from the DeKAF study. Am J Transplant 2010; 10: 315.
235. Gaston RS, Cecka JM, Kasiske BL, et al. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 2010; 90: 68.
236. Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 2012; 12: 1157.
237. Sellarés J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 2012; 12: 388.
238. Gloor JM, Sethi S, Stegall MD, et al. Transplant glomerulopathy: subclinical incidence and association with alloantibody. Am J Transplant 2007; 7: 2124.
239. Loupy A, Suberbielle-Boissel C, Hill GS, et al. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant 2009; 9: 2561.
240. Gloor JM, Cosio FG, Rea DJ, et al. Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation. Am J Transplant 2006; 6: 1841.
241. Walsh RC, Brailey P, Girnita A, et al. Early and late acute antibodymediated rejection differ immunologically and in response to proteasome inhibition. Transplantation 2011; 91: 1218.
242. Gill JS, Landsberg D, Johnston O, et al. Screening for de novo antihuman leukocyte antigen antibodies in nonsensitized kidney transplant recipients does not predict acute rejection. Transplantation 2010; 89: 178.
243. Li X, Ishida H, Yamaguchi Y, et al. Poor graft outcome in recipients with de novo donor-specific anti-HLA antibodies after living related kidney transplantation. Transpl Int 2008; 21: 1145.
244. Hidalgo LG, Campbell PM, Sis B, et al. De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant 2009; 9: 2532.
245. Hourmant M, Cesbron-Gautier A, Terasaki PI, et al. Frequency and clinical implications of development of donor-specific and nondonor-specific HLA antibodies after kidney transplantation. J Am Soc Nephrol 2005; 16: 2804.
246. Cardarelli F, Pascual M, Tolkoff-Rubin N, et al. Prevalence and significance of anti-HLA and donor-specific antibodies long-term after renal transplantation. Transpl Int 2005; 18: 532.
247. Campos EF, Tedesco-Silva H, Machado PG, et al. Post-transplant anti-HLA class II antibodies as risk factor for late kidney allograft failure. Am J Transplant 2006; 6: 2316.
248. Lachmann N, Terasaki PI, Budde K, et al. Anti-human leukocyte antigen and donor-specific antibodies detected by Luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation 2009; 87: 1505.
249. Lee PC, Terasaki PI, Takemoto SK, et al. All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies. Transplantation 2002; 74: 1192.
250. Mizutani K, Terasaki P, Rosen A, et al. Serial ten-year follow-up of HLA and MICA antibody production prior to kidney graft failure. Am J Transplant 2005; 5: 2265.
251. Terasaki PI, Ozawa M, Castro R. Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am J Transplant 2007; 7: 408.
252. Liefeldt L, Brakemeier S, Glander P, et al. Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney Transplantation. Am J Transplant 2012; 12: 1192.
253. Lefaucheur C, Nochy D, Andrade J, et al. Comparison of combination plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am J Transplant 2009; 9: 1099.
254. Kimball PM, Baker MA, Wagner MB, et al. Surveillance of alloantibodies after transplantation identifies the risk of chronic rejection. Kidney Int 2011; 79: 1131.
255. Everly MJ, Everly JJ, Arend LJ, et al. Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant 2009; 9: 1063.
256. Everly MJ, Rebellato LM, Ozawa M, et al. Beyond histology: lowering human leukocyte antigen antibody to improve renal allograft survival in acute rejection. Transplantation 2010; 89: 962.
257. Martin S, Dyer PA, Mallick NP, et al. Post-transplant antidonor lymphocytotoxic antibody production in relation to graft outcome. Transplantation 1987; 44: 50.
258. Worthington JE, Martin S, Al-HusseiniDM, et al. Post-transplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome. Transplantation 2003; 75: 1034.
259. Terasaki PI, Ozawa M. Predicting kidney graft failure by HLA antibodies: a prospective trial. Am J Transplant 2004; 4: 438.
260. Moreso F, Carrera M, Goma M, et al. Early subclinical rejection as a risk factor for late chronic humoral rejection. Transplantation 2012; 93: 41.
261. Ho EK, Vlad G, Vasilescu ER, et al. Pre-and post-transplantation allosensitization in heart allograft recipients: major impact of de novo alloantibody production on allograft survival. Hum Immunol 2011; 72: 5.
262. Collins AB, Chicano SL, Cornell LD, et al. Putative antibody-mediated rejection withC4d deposition in HLA-identical, ABO-compatible renal allografts. Transplant Proc 2006; 38: 3427.
263. Grafft CA, Cornell LD, Gloor JM, et al. Antibody-mediated rejection following transplantation from an HLA-identical sibling. Nephrol Dial Transplant 2010; 25: 307.
264. Ozawa M, Rebellato LM, Terasaki PI, et al. Longitudinal testing of 266 renal allograft patients for HLA and MICA antibodies: Greenville experience. In: Clinical Transplants. Los Angeles: The Terasaki Foundation Laboratory; 2006. pp. 265.
265. Mizutani K, Shibata L, Ozawa M, et al. Detection of HLA and MICA antibodies before kidney graft failure. In: Clinical Transplants. Los Angeles: The Terasaki Foundation Laboratory; 2006. pp. 255.
266. Everly MJ, Everly JJ, Susskind B, et al. Bortezomib provides effective therapy for antibody and cell-mediated acute rejection. Transplantation 2008; 86: 1754.
267. Archdeacon P, Chan M, Neuland C, et al. Summary of FDA antibodymediated rejection workshop. Am J Transplant 2011; 11: 896.
268. Stegall MD, Gloor J, Winters JL, et al. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006; 6: 346.
269. Marfo K, Lu A, Ling M, et al. Desensitization protocols and their outcome. Clin J Am Soc Nephrol 2011; 6: 922.
270. Heidt S, Roelen DL, De Vaal YJH, et al. A novel ELISPOT assay to quantify HLA-specific B cells in HLA-immunized individuals. Am J Transplant 2012; 12: 1469.
271. Perry DK, Pollinger HS, Burns JM, et al. Two novel assays of alloantibody-secreting cells demonstrating resistance to desensitization with IVIG and rATG. Am J Transplant 2008; 8: 133.
272. Terasaki PI. A personal perspective: 100 year history of the humoral theory of transplantation. Transplantation 2012; 93: 751.
273. Russell PS, Chase CM, Winn HJ, et al. Coronary atherosclerosis in transplanted mouse hearts. II. Importance of humoral immunity. J Immunol 1994; 152: 5135.
274. Harmer AW, Koffman CG, Heads AJ, et al. Sensitization to HLA antigens occurs in 95% of primary renal transplant rejections. Transplant Proc 1995; 27: 666.
275. Morales-Buenrostro LE, Castro R, Terasaki PI. A single human leukocyte antibody test after heart or lung transplantation is predictive of survival. Transplantation 2008; 85: 478.
276. Hönger G, Hopfer H, Arnold ML, et al. Pre-transplant IgG subclasses of donor-specific human leukocyte antigen antibodies and development of antibody-mediated rejection. Transplantation 2011; 92: 41.